MT-ND3
ENSG00000198840
Target class
Enzyme
Chromosome
Mitochondrial
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- MT-ND3
- Gene name
- Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3
- Gene symbol
- MT-ND3
- Previous gene symbols
- MTND3
- Protein name
- NADH-ubiquinone oxidoreductase chain 3 (EC 7.1.1.2) (NADH dehydrogenase subunit 3)
- ND3
- NAD3
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase core subunits|Mitochondrially encoded protein coding genes
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Uncertain
- Highest tissue expression
- 37,220.7
- Tissue specificity (Gini)
- 0.263
- Tissue specificity (tau)
- 0.559
- KEGG gene identifiers
- hsa:4537
- Protein interaction confidence
- 0.92914
- Protein interaction partners
- 107
- R-HSA-5419276
- R-HSA-611105
- R-HSA-6799198
- End position
- 10404
- Start position
- 10059
- Chromosome
- Mitochondrial
- Strand
- Forward
- Mitochondrion inner membrane
- Multi-pass membrane protein .
- Tissue specificity (tau)
- 0.559258
- Expression inequality (Gini)
- 0.262988
Expression in transcripts per million
- Kidney - Medulla
- 37,220.7
- Heart - Left Ventricle
- 32,080.2
- Kidney - Cortex
- 31,942.9
- Heart - Atrial Appendage
- 29,556.4
- Brain - Putamen (basal ganglia)
- 28,747.8
Expression in transcripts per million
- Kidney - Medulla37,220.7
- Heart - Left Ventricle32,080.2
- Kidney - Cortex31,942.9
- Heart - Atrial Appendage29,556.4
- Brain - Putamen (basal ganglia)28,747.8
- Brain - Caudate (basal ganglia)27,173.4
- Brain - Nucleus accumbens (basal ganglia)26,233
- Brain - Hippocampus25,635.4
- Brain - Amygdala25,151.3
- Brain - Hypothalamus25,066.8
- Brain - Anterior cingulate cortex (BA24)23,958.8
- Brain - Substantia nigra23,795
- Brain - Spinal cord (cervical c-1)22,764.4
- Adrenal Gland22,106.5
- Adipose - Visceral (Omentum)21,840.6
- Brain - Frontal Cortex (BA9)20,599.3
- Brain - Cortex19,969.8
- Stomach19,735.1
- Prostate19,602.8
- Liver19,264.4
- Colon - Sigmoid19,221.9
- Esophagus - Muscularis18,288.5
- Breast - Mammary Tissue18,080.4
- Colon - Transverse17,563.4
- Esophagus - Gastroesophageal Junction17,436.8
And 29 more, listed on the interactive page.
Biological processes
- GO:0006120
- GO:0005739
- GO:0005743
- GO:0045271
- GO:0005515
- GO:0008137
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor